IOVA Iovance Biotherapeutics Inc.

21.95
-1.02  -4%
Previous Close 22.97
Open 23.57
Price To Book 7.81
Market Cap 2,769,978,384
Shares 126,194,915
Volume 2,926,370
Short Ratio
Av. Daily Volume 1,342,938
Stock charts supplied by TradingView

NewsSee all news

  1. Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    -  41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy -             - Median duration of response (DOR) was not reached as assessed

  2. Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting

    - Cohort 2 objective response rate (ORR) as determined by independent review committee (IRC) was 35 percent, which aligns well with the investigator assessed ORR of 36 percent - - Median duration of response (DOR)

  3. Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November

    SAN CARLOS, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)

  4. Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results

                - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01 melanoma trial -                         -

  5. Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019

    SAN CARLOS, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initiated March 2017. Poster session at SITC November 10, 2017. Data released January 24, 2018 showed 3/8 PRs.
LN-145
Head and neck cancer
Phase 2 pivotal cohort enrolment to be completed 1Q 2020. Cohort 2 data noted 41% ORR in patients refractory to anti-PD1/L1 - November 21, 2019.
LN-144 - lifileucel
Refractory metastatic melanoma
Phase 2 update due at ASCO June 1, 2019, 8am. Data released May 31, 2019 noted ORR 44%; CR 11%. BLA filing due 2H 2020.
LN-145
Cervical cancer

Latest News

  1. Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    -  41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy -             - Median duration of response (DOR) was not reached as assessed

  2. Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting

    - Cohort 2 objective response rate (ORR) as determined by independent review committee (IRC) was 35 percent, which aligns well with the investigator assessed ORR of 36 percent - - Median duration of response (DOR)

  3. Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November

    SAN CARLOS, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)

  4. Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results

                - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01 melanoma trial -                         -

  5. Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019

    SAN CARLOS, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)

  6. Iovance Biotherapeutics to Present at Upcoming Conferences

    SAN CARLOS, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte

  7. Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September

    SAN CARLOS, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)